Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1

DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance

(2015) Euan A. Stronach et al.   NEOPLASIA

The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

(2013) Ruth Thompson et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Another fork in the road—life or death decisions by the tumour suppressor p53

(2013) Luis A Carvajal et al.   EMBO REPORTS

mTORC1 Status Dictates Tumor Response to Targeted Therapeutics

(2013) I. Kelsey et al.   Science Signaling

Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum

(2012) Ahmed Y. Ali et al.   Annals of the New York Academy of Sciences

DNA damage-induced CHK1 autophosphorylation at Ser296 is regulated by an intramolecular mechanism

(2012) Naoyuki Okita et al.   FEBS LETTERS

Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells

(2012) S Origanti et al.   ONCOGENE

Akt: A Double-Edged Sword in Cell Proliferation and Genome Stability

(2012) Naihan Xu et al.   Journal of Oncology

Akt, FoxO and regulation of apoptosis

(2011) Xinbo Zhang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Targeting the S and G2 checkpoint to treat cancer

(2011) Tao Chen et al.   DRUG DISCOVERY TODAY

The proliferation rate paradox in antimitotic chemotherapy

(2011) Timothy J. Mitchison   MOLECULAR BIOLOGY OF THE CELL

Phosphorylation of Tip60 by GSK-3 Determines the Induction of PUMA and Apoptosis by p53

(2011) Céline Charvet et al.   MOLECULAR CELL

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

Akt Activation Emulates Chk1 Inhibition and Bcl2 Overexpression and Abrogates G2 Cell Cycle Checkpoint by Inhibiting BRCA1 Foci

(2010) Ivana Tonic et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis

(2010) Andrea Alimonti et al.   JOURNAL OF CLINICAL INVESTIGATION

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Novel therapeutic agents for osteosarcoma

(2009) Kathleen O’Day et al.   Expert Review of Anticancer Therapy

Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells

(2009) Hui-Fang Li et al.   Radiation Oncology

Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest

(2008) A. A. Levesque et al.   MOLECULAR CANCER THERAPEUTICS

PKB and the mitochondria: AKTing on apoptosis

(2007) Arnaud Parcellier et al.   CELLULAR SIGNALLING